- Statin therapies prevent both primary and secondary cardiovascular disease.
- However, long term safety concerns has led to discontinuation of statin therapy, nonadherence to therapy, along with hesitations about initiating therapy.
- Most common reported adverse events are muscle-related (statin-associated muscle symptoms, SAMS).
- SAMS-Clinical Index may help clinicians determine the likelihood that a patient’s muscle symptoms (myalgia or myopathy) are attributable to statin usage. SAMS-CI is derived by a questionnaire that evaluates muscle symptoms encompassing location and pattern of muscle symptoms, timing of onset and withdrawal of symptoms in relation to statin therapy and changes in statin regimen.
- Overwhelming evidence shows benefits of statin therapy outweigh any potential risks of statin therapy, therefore clinicians should work diligently with patients in a shared-decision model to ensure they adhere to therapy .
Original article: Nat Rev Cardiol. 2018 Dec;15(12):757-769.
Reference for figure: Adapted from Nat Rev Cardiol. 2018 Dec;15(12):757-769.
Author: Nazanin Hakimzadeh